

			Sale estimates million DKR				
	Royalty	Peaksale	2021	2022	2023	2024	2025
Daratumumab (CD38) MM	17%	10B\$USD	6500	7800	8500	9200	9900
AL Amyloidosis (Dara)							
Non MM blod cancers : phase 2 (Dara)							
Ofatumumab (CD20) MS	10%	2.5B\$USD	250	500	750	1000	1250
Teprotumumab (IGF-1R) Thyroid eye disease	7%	3.5B\$USD	400	600	800	1000	1736
Amivantamab	10%	1B\$USD	75	155	310	620	620
Tisotumab Vedotin (Cervical cancer)	50/50	500M\$USD	90	180	375	750	1550
Ovarian Cancer	50/50						
Solid tumors	50/50						
Epcoritamab - 1st sale Q4 - 2022	50/50	5B\$USD	0	250	1800	3600	7200
HexaBody-CD38							
Total			7315	9485	12535	16170	22256

Revision 5 - March 25-2021